NGeneBio Co., Ltd.

Research NGeneBio Co., Ltd. (354200.KQ) on Bullrun: market cap KRW 15.07B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 15.07B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 15.07Bn/an/an/a

Dividend history

About NGeneBio Co., Ltd.

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is NGeneBio Co., Ltd.'s market cap?

NGeneBio Co., Ltd.'s market capitalization is KRW 15.07B.

What does NGeneBio Co., Ltd. do?

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen.